Catalent Acquires Paragon Bioservices for $1.2 Billion
May 20, 2019
Catalent, Inc. completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing partner for gene therapies, expanding Catalent’s biologics and gene therapy capabilities. Paragon’s Baltimore-area facilities and ~380 employees will join Catalent’s global biologics platform, while Catalent secured financing including incremental term loans and a convertible preferred issuance to Leonard Green & Partners to support the transaction.
- Buyers
- Catalent, Inc.
- Targets
- Paragon Bioservices, Inc.
- Industry
- Biotechnology
- Location
- Maryland, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Getinge Acquires Paragonix Technologies
August 22, 2024
Medical Devices
Getinge has completed the acquisition of Paragonix Technologies, a U.S. developer of organ preservation devices and transplant logistics services, for an estimated total consideration of USD 477 million (including earn-outs). The deal will make Paragonix a wholly owned subsidiary of Getinge and is intended to expand Getinge's transplant product portfolio and bring Paragonix's technologies to new global markets.
-
Elevance Health Acquires Paragon Healthcare
March 11, 2024
Healthcare Services
Elevance Health closed its acquisition of Paragon Healthcare, an infusion services and injectable therapy provider. Following the deal, Paragon Healthcare will operate as part of CarelonRx, Elevance’s pharmacy services segment, with plans to expand geographically and scale multi-site infusion services and specialty pharmacy capabilities.
-
Quantum Lifecycle Partners Acquires Paragon Bay Group
January 11, 2024
Environmental Services
Quantum Lifecycle Partners LP has acquired Paragon Bay Group Inc., a North Bay, Ontario specialist in testing, in‑warranty repair, asset recovery and forward/reverse logistics for electronics OEMs. Sixty Paragon Bay employees join Quantum as the deal expands Quantum's repair, 3PL logistics and IT device maintenance capabilities across Canada.
-
Merck Acquires Pandion Therapeutics
February 25, 2021
Biotechnology
Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.
-
Catalent Acquires Delphi Genetics to Add Plasmid DNA Capabilities
February 23, 2021
Biotechnology
Catalent has agreed to acquire 100% of Delphi Genetics, a Belgium-based plasmid DNA (pDNA) CDMO, and will integrate Delphi's pDNA development and cGMP manufacturing capabilities into its Cell & Gene Therapy business. The deal also supports Catalent's launch of pDNA services at its Rockville, Maryland facility, expanding integrated pDNA supply across Europe and the U.S.
-
Aptean Acquires Paragon Software Systems
March 5, 2020
Software
Aptean, a global provider of industry-specific enterprise software, has acquired UK-based Paragon Software Systems, a specialist in transportation management, routing and scheduling solutions. The deal expands Aptean’s logistics and route-optimization capabilities and furthers its presence in the European market, adding Paragon’s installed base and customers in food & beverage, retail, distribution and pharmaceutical sectors.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.